KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Debt (2020 - 2025)

Historic Total Debt for Regeneron Pharmaceuticals (REGN) over the last 6 years, with Q4 2025 value amounting to $2.0 billion.

  • Regeneron Pharmaceuticals' Total Debt rose 7.56% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 7.56%. This contributed to the annual value of $2.0 billion for FY2025, which is 7.56% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Total Debt stood at $2.0 billion for Q4 2025, which was up 7.56% from $2.0 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Total Debt's 5-year high stood at $2.0 billion during Q3 2025, with a 5-year trough of $2.0 billion in Q1 2021.
  • Moreover, its 5-year median value for Total Debt was $2.0 billion (2023), whereas its average is $2.0 billion.
  • The largest annual percentage gain for Regeneron Pharmaceuticals' Total Debt in the last 5 years was 3194.67% (2021), contrasted with its biggest fall of 6.57% (2021).
  • Over the past 5 years, Regeneron Pharmaceuticals' Total Debt (Quarter) stood at $2.0 billion in 2021, then increased by 0.07% to $2.0 billion in 2022, then rose by 0.08% to $2.0 billion in 2023, then rose by 0.08% to $2.0 billion in 2024, then grew by 0.08% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q4 2025, $2.0 billion for Q3 2025, and $2.0 billion during Q2 2025.